In a report released today, Justin Keywood from Stifel Nicolaus maintained a Buy rating on Greenbrook Tms (GBOKD – Research Report), with a price target of C$22.00. The company’s shares closed last Wednesday at $15.04.
Keywood has an average return of 103.2% when recommending Greenbrook Tms.
According to TipRanks.com, Keywood is ranked #295 out of 7342 analysts.
Greenbrook Tms has an analyst consensus of Strong Buy, with a price target consensus of $19.40, representing a 28.3% upside. In a report issued on February 26, Desjardins also reiterated a Buy rating on the stock with a C$24.00 price target.
The company has a one-year high of $16.25 and a one-year low of $10.51. Currently, Greenbrook Tms has an average volume of 1,313.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Greenbrook Tms, Inc. engages in the provision of transcranial magnetic stimulation, an FDA-cleared, non-invasive therapy for the treatment of major depressive disorder. It operates through Outpatient Mental Health Service Centers segment. The company was founded on February 9, 2018 and is headquartered in Toronto, Canada.